The position of the amino group on the benzene ring is critical for mesalamine's improvement of replication fidelity

Inflammatory Bowel Diseases

Volumn 16, Issue 4, 2010, Pages 576-582

  Campregher, Christoph ^a   Luciani, Maria Gloria ^a,b   Biesenbach, Peter ^a   Evstatiev, Rayko ^a   Lyakhovich, Alex ^a   Gasche, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

3 ASA; 4 ASA; 5 ASA; Cell cycle; Chemoprevention; Mesalazine; Replication

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 AMINOSALICYLIC ACID; 5 ACETAMIDOSALICYLIC ACID; AMINOSALICYLIC ACID; AMINOSALICYLIC ACID DERIVATIVE; BENZENE; CLASPIN; LUCIGENIN; MESALAZINE; NUCLEAR PROTEIN; PROTEIN; PROTEIN P53; REPLICATION FACTOR A; SUPEROXIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE S PHASE; CELL GROWTH; CELL POPULATION; CELL STRAIN HCT116; CELL STRAIN HT29; CHEMOLUMINESCENCE; COLON MUCOSA; COMPARATIVE STUDY; CONTROLLED STUDY; EPITHELIUM CELL; ERROR; FLOW CYTOMETRY; GROWTH INHIBITION; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZENE; BLOTTING, WESTERN; CELL CYCLE; CELL PROLIFERATION; DNA REPLICATION; FLOW CYTOMETRY; HT29 CELLS; HUMANS; MESALAMINE; MICROSATELLITE REPEATS; NEUTROPHILS; REPLICATION PROTEIN A; SUPEROXIDES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77949513549     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.21112     Document Type: Article

References (33)

1. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892-895.
2. Svartz N. Salazyopyrin, a new sulfanilamide preparation. A. Therapeutic results in rheumatic polyarthritis. B. Therapeutic results in ulcerative colitis. C. Toxic manifestations in treatment with sulfanilamide preparation. Acta Med Scand. 1942;110:557-590.
3. Rubin DT, Cruz-Correa MR, Gasche C, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis. 2007;14:265-274.
4. Terdiman JP, Steinbuch M, Blumentals WA, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367-371.
5. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941-1949.
6. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and meta-analysis of observational studies. Am J Gastroenterol. 2005;100:1345-1353.
7. Allgayer H, Ahnfelt NO, Kruis W, et al. Colonic N-acetylation of 5-aminosalicylic acid in inflammatory bowel disease. Gastroenterology. 1989;97:38-41.
8. Layer PH, Goebell H, Keller J, et al. Delivery and fate of oral mesalamine microgranules within the human small intestine. Gastroenterology. 1995;108:1427-1433.
9. Kruis W, Kiudelis G, Racz I, et al. Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomised, non-inferiority trial. Gut. 2009;58:233-240.
10. Beeken W, Howard D, Bigelow J, et al. Controlled trial of 4-ASA in ulcerative colitis. Dig Dis Sci. 1997;42:354-358.
11. Miyachi Y, Yoshioka A, Imamura S, et al. Effect of sulphasalazine and its metabolites on the generation of reactive oxygen species. Gut. 1987;28:190-195.
12. Kennedy M, Wilson L, Szabo C, et al. 5-Aminosalicylic acid inhibits iNOS transcription in human intestinal epithelial cells. Int J Mol Med. 1999;4:437-443.
13. Ancha HR, Kurella RR, McKimmey CC, et al. Effects of N-acetylcysteine plus mesalamine on prostaglandin synthesis and nitric oxide generation in TNBS-induced colitis in rats. Dig Dis Sci. 2009;54:758-766.
14. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappaB activation in mouse colonocytes. Gastroenterology. 1999;116:602-609.
15. Swidsinski A, Loening-Baucke V, Bengmark S, et al. Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis. Inflamm Bowel Dis. 2007;13:51-56.
16. Monteleone G, Franchi L, Fina D, et al. Silencing of SH-PTP2 defines a crucial role in the inactivation of epidermal growth factor receptor by 5-aminosalicylic acid in colon cancer cells. Cell Death Differ. 2006;13:202-211.
17. Bos CL, Diks SH, Hardwick JC, et al. Protein phosphatase 2A is required for mesalazine-dependent inhibition of Wnt/beta-catenin pathway activity. Carcinogenesis. 2006;27:2371-2382.
18. Gasche C, Goel A, Natarajan L, et al. Mesalazine improves replication fidelity in cultured colorectal cells. Cancer Res. 2005;65:3993-3997.
19. Luciani MG, Campregher C, Fortune JM, et al. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology. 2007;132:221-235.
20. Wermuth CG, Ganelli CR, Lindberg P, et al. Glossary of terms used in medicinal chemistry (IUPAC Recommendations 1997). Annu Rep Med Chem. 1998;33:385-395.
21. Rousseaux C, Lefebvre B, Dubuquoy L, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator- activated receptor-gamma. J Exp Med. 2005;201:1205-1215.
22. Desreumaux P, Ghosh S. Review article: mode of action and delivery of 5-aminosalicylic acid - new evidence. Aliment Pharmacol Ther. 2006;24(suppl 1):2-9.
23. Gasche C, Chang CL, Natarajan L, et al. Identification of frame-shift intermediate mutant cells. Proc Natl Acad Sci USA. 2003;100:1914-1919.
24. Campregher C, Luciani MG, Gasche C. Activated neutrophils induce an hMSH2-dependent G2/M checkpoint arrest and replication errors at a (CA)13-repeat in colon epithelial cells. Gut. 2008;57:780-787.
25. Keshavarzian A, Banan A, Farhadi A, et al. Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of patients with inflammatory bowel disease. Gut. 2003;52:720-728.
26. Gasche C, Chang CL, Rhees J, et al. Oxidative stress increases frame-shift mutations in human colorectal cancer cells. Cancer Res. 2001;61:7444-7448.
27. Cortez D, Guntuku S, Qin J, et al. ATR and ATRIP: partners in checkpoint signaling. Science. 2001;294:1713-1716.
28. Chini CC, Chen J. Human claspin is required for replication checkpoint control. J Biol Chem. 2003;278:30057-30062.
29. Lee J, Kumagai A, Dunphy WG. Claspin, a Chk1-regulatory protein, monitors DNA replication on chromatin independently of RPA, ATR, and Rad17. Mol Cell. 2003;11:329-340.
30. Reinacher-Schick A, Schoeneck A, Graeven U, et al. Mesalazine causes a mitotic arrest and induces caspase-dependent apoptosis in colon carcinoma cells. Carcinogenesis. 2003;24:443-451.
31. Reinacher-Schick A, Seidensticker F, Petrasch S, et al. Mesalazine changes apoptosis and proliferation in normal mucosa of patients with sporadic polyps of the large bowel. Endoscopy. 2000;32:245-254.
32. Stolfi C, Fina D, Caruso R, et al. Mesalazine negatively regulates CDC25A protein expression and promotes accumulation of colon cancer cells in S phase. Carcinogenesis. 2008;29:1258-1266.
33. Gasche C. Review article: the chemoprevention of colorectal carcinoma. Aliment Pharmacol Ther. 2004;20(suppl 4):31-35.